Comparison of safety and efficacy of lithium and lithium with SSRI in bipolar disorder

Rajesh Vallabhaeni; Sanket G. Malu; Basavambika V. Anandi; Santhoshkumar R. Jeevanagi

doi:10.18203/2319-2003.ijbcp20250479

Authors

Rajesh Vallabhaeni Department of Pharmacology, M. R. Medical College, Kalaburagi, Karnataka, India
Sanket G. Malu Department of Pharmacology, M. R. Medical College, Kalaburagi, Karnataka, India
Basavambika V. Anandi Department of Pharmacology, M. R. Medical College, Kalaburagi, Karnataka, India
Santhoshkumar R. Jeevanagi Department of Pharmacology, M. R. Medical College, Kalaburagi, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20250479

Keywords:

Antidepressant, Mood disorder, Montgomery–Åsberg depression rating scale, Quality of life scale

Abstract

Background: Bipolar disorder is a serious psychiatric illness resulting in depression and mania that affects approximately 1.5% of the world population and represents a significant source of individual morbidity and mortality. Hence the present study was undertaken to compare the safety and efficacy of Lithium and Lithium with SSRI in Bipolar disorder.

Methods: Study was conducted in outpatient department, Department of Psychiatry, Basaveshwar Teaching and General Hospital attached to Mahadevappa Rampure Medical College, Kalaburagi, Karnataka. After obtaining Informed and written consent, Total 60 patients were selected after inclusion and exclusion criteria. Patients were diagnosed according to MINI and were divided into 2 groups, Group 1: Patients receiving Lithium 800-1200 group 2: Patients receiving Lithium + Escitalopram 20 mg/those intolerants to Escitalopram were given Sertraline 100 mg. Both groups were followed up regularly at interval of 1, 3, 5 and 8 weeks

Results: Findings were tabulated according to comparative tools like MADRS, YMRS, C-SSRS, CGI- BP & QOLS, they were subjected to t-test and ANOVA to verify the outcome

Conclusions: Patients treated with Lithium + SSRI showed to have better quality of life and had a lower risk of switch to manic episodes.

Metrics

Metrics Loading ...

References

Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251-69. DOI: https://doi.org/10.1177/2045125318769235

Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;36:349-52. DOI: https://doi.org/10.5694/j.1326-5377.1949.tb36912.x

Chevalier N, Guillou P, Viguié C, Fini JB, Sachs LM, Michel-Caillet C, et al. Lithium and endocrine disruption: A concern for human health. Environment International. 2024 :108861. DOI: https://doi.org/10.1016/j.envint.2024.108861

Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-7. DOI: https://doi.org/10.4088/PCC.v03n0105

Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disorder. 2003;5(6):421-33. DOI: https://doi.org/10.1046/j.1399-5618.2003.00074.x

Ghaemi S N, Rosenquist KJ, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar vs unipolar depression. Am J Psychiatry 2004;161:163-5. DOI: https://doi.org/10.1176/appi.ajp.161.1.163

7.Angst J.Bipolar disorder in DSM-5:Strengths , problems and perspectives .Int J Bipolar Disorder. 2013;1:12. DOI: https://doi.org/10.1186/2194-7511-1-12

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22-33.

Fernandes F, Carneiro A, Campos RN, Soeiro-de-Souza MG, Barros VB, Moreno RA. SIGMA-VB: Validity and reliability of the Brazilian Portuguese version of the Montgomery-Åsberg depression rating scale using the structured interview guide for the MADRS. Brazilian J Psyc. 2019;41:297-302. DOI: https://doi.org/10.1590/1516-4446-2018-0105

Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35. DOI: https://doi.org/10.1192/bjp.133.5.429

Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-77. DOI: https://doi.org/10.1176/appi.ajp.2011.10111704

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 200;4(7):28-37.

Burckhardt CS, Anderson KL. The Quality-of-Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes. 2003;3(1):60. DOI: https://doi.org/10.1186/1477-7525-1-60

Sach GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L. Effectiveness of adjuvant antidepressant treatment for bipolar disorder. NEJM. 2007;356:1711-22. DOI: https://doi.org/10.1056/NEJMoa064135

Young LT, Joffe RT, Robb JC, Macqueen GM, Marriott M, Patelis-Siotis I. Double blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patient with bipolar disorder. Am J Psychiatry 2000;157:124-6. DOI: https://doi.org/10.1176/ajp.157.1.124